Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2025)
Historic Free Cash Flow for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$117.6 million.
- Recursion Pharmaceuticals' Free Cash Flow fell 8436.83% to -$117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$447.7 million, marking a year-over-year decrease of 3473.01%. This contributed to the annual value of -$372.9 million for FY2024, which is 2439.96% down from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Free Cash Flow is -$117.6 million, which was down 8436.83% from -$79.6 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Free Cash Flow ranged from a high of $73.0 million in Q1 2022 and a low of -$133.8 million during Q1 2025
- In the last 5 years, Recursion Pharmaceuticals' Free Cash Flow had a median value of -$73.7 million in 2023 and averaged -$69.6 million.
- Per our database at Business Quant, Recursion Pharmaceuticals' Free Cash Flow tumbled by 144306.18% in 2021 and then skyrocketed by 24559.41% in 2022.
- Over the past 5 years, Recursion Pharmaceuticals' Free Cash Flow (Quarter) stood at -$65.6 million in 2021, then rose by 19.65% to -$52.7 million in 2022, then tumbled by 44.41% to -$76.1 million in 2023, then crashed by 53.3% to -$116.7 million in 2024, then decreased by 0.75% to -$117.6 million in 2025.
- Its Free Cash Flow stands at -$117.6 million for Q3 2025, versus -$79.6 million for Q2 2025 and -$133.8 million for Q1 2025.